Epstein Secrets

sing levels in the marketplace. is From John D. Emory Sr., F.R. Dengel 111, and John D. Emory Jr., 'Expanded Study of the Value of Marketability as Illustrated in Initial Public Offerings of Common Stock; May 1997 through December 2000," Business Valuation Review, December 2001, pp. 4-20; and John D. Emory

511,388 516,110 517,399 518,616 519,733 Full.year caprx ar % of rnwnme 3.4% 1.4% 1.4% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% Remonahlenem Cheek Guideline Company Indications 0.6% to 8.7% A•crap: 2.9% Median 2.2% 35 EFTA00307430 F: F. ge"liAiAri 0000,AZA4g 00,0, 20.122q4 _zn„

sing levels in the marketplace. is From John D. Emory Sr., F.R. Dengel 111, and John D. Emory Jr., 'Expanded Study of the Value of Marketability as Illustrated in Initial Public Offerings of Common Stock; May 1997 through December 2000," Business Valuation Review, December 2001, pp. 4-20; and John D. Emory

511,388 516,110 517,399 518,616 519,733 Full.year caprx ar % of rnwnme 3.4% 1.4% 1.4% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% Remonahlenem Cheek Guideline Company Indications 0.6% to 8.7% A•crap: 2.9% Median 2.2% 35 EFTA00307329 F: F. ge"liAiAri 0000,AZA4g 00,0, 20.122q4 _zn„

sing levels in the marketplace. is From John D. Emory Sr., F.R. Dengel 111, and John D. Emory Jr., 'Expanded Study of the Value of Marketability as Illustrated in Initial Public Offerings of Common Stock; May 1997 through December 2000," Business Valuation Review, December 2001, pp. 4-20; and John D. Emory

511,388 516,110 517,399 518,616 519,733 Full.year caprx ar % of rnwnme 3.4% 1.4% 1.4% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% Remonahlenem Cheek Guideline Company Indications 0.6% to 8.7% A•crap: 2.9% Median 2.2% 35 EFTA00307228 F: F. ge"liAiAri 0000,AZA4g 00,0, 20.122q4 _zn„